Artimplant USA Medical Advisory Board

Artimplant has formed a Medical Advisory Board (MAB) in the US comprising
leading surgeons with a diversity of expertise in the field of orthopedic and
podiatric medicine. The MAB will provide feedback and guidance to Artimplant and
develop knowledge of Artimplant's products.

The members of the Artimplant USA Medical Advisory Board (MAB) are: Eric Giza,
MD, Edward Diao, MD, Joseph M. Berman, MD, Janos P. Ertl MD, Wayne Gersoff MD,
Keith Jacobson, DPM, Jason R. Miller, DPM and Lars Peterson, PhD, MD. A closer
presentation of the MAB members can be found on Artimplant's website
www.artimplant.com/about-us.

“The Medical Advisory Board’s collective expertise, insights and real-world
clinical experience will be instrumental as we continue to grow,” said Kjell
Thörnbring, CEO, Artimplant AB. “We are honored to have assembled such an
impressive group of key opinion leaders who will help us increase the knowledge
about the use of our products in the US market.”

For further information, please contact:
Kjell Thörnbring, CEO
E-mail: kjell.thornbring@artimplant.com
Telephone: +46 703 119 025

Further information is available at www.artimplant.com where you can also
subscribe to future press releases; www.artimplant.com/investors-media/subscribe
-to-press-releases.html

Artimplant
Artimplant is a biomaterials company focused on solutions to problems in
orthopedics. We restore health through the development, production and marketing
of degradable implants that regenerate body functions and improve quality of
life. Our products, made from Artelon®, meet unmet clinical needs and are
marketed in a growing number of therapy areas. Artimplant produces implants for
treatment of osteoarthritis in hands and feet as well as shoulder and other soft
tissue injuries.

Artimplant is a public company, listed on NASDAQ OMX Stockholm in the Small Cap
segment and in the healthcare sector.

Forward-looking statements
This press release contains forward-looking statements as defined in the U.S.
Private Securities Litigation Reform Act of 1995. Readers are cautioned not to
place undue reliance on these forward-looking statements. Actual results may
differ materially from those indicated by these forward-looking statements as a
result of risks and uncertainties impacting on the Company's business, including
increased competition; the ability of the Company to expand its operations and
to attract and retain qualified professionals; technological obsolescence;
general economic conditions; and other risks detailed from time to time in the
Company's filings.

This is information that Artimplant will make public pursuant to the Swedish
Financial Instruments Act and the Swedish Securities Exchange and Clearing
Operations Act and/or stock market agreements. Information was made available
for publication on November 27, 2012 at 1 pm (Swedish time).